1Philip T, Guglielmi , Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. N Engl J Med, 1995, 333:1540.
2Vose J, Rizzo D, Wu JT, et al. Autologous transplantation for diffuse aggressive non hodgkin's lymphoma in first relapse or second remission. Biol blood marrow transplant, 2004,10:116.
3Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood, 2004,103 : 777.
4Peniket AJ,Ruiz de Elvira MC, Taghipoue G, et al. an EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated eith a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation, 2003,31 : 667.
5Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood, 2004,104:3797.
6Rodriguez R, Nademanee A, Ruel N, et al. Comparison of Reduced-intensity and conventional myeloablative Regimens for allogeneictransplantationin Non-Hodgkin's lymphoma. Biol blood marrowtransplant, 2006,12 : 1326.
7Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 2004,104: 3865.
8Levine J, Harris R, Loberiza FR, et al. A comparason of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood, 2003,101 : 2476.
9Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Marrow Transplant Registries. Bri J Haematol, 2003,120 : 793.
10Persky D, Portlock CS, Lessac-Chenen S, et al. The utility of consolidative upfront high dose chemotherapy and ASCT in patients with mantle cell lymphoma (MCL). Blood, 2005, 106: 2072a.
